CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS

CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS

The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinuma...

Full description

Bibliographic Details
Main Authors: E. I. Alexeeva, R. V. Denisova, T. V. Sleptsova, T. M. Bzarova, K. B. Isaeva, E. V. Mitenko, E. G. Chistyakova, A. M. Chomakhidze, N. I. Taybulatov, A. N. Fetisova, O. L. Lomakina, S. I. Valieva
Format: Article
Language:English
Published: Paediatrician Publishers, LLC 2014-03-01
Series:Pediatričeskaâ Farmakologiâ
Subjects:
systemic juvenile idiopathic arthritis
canakinumab
children
Online Access:https://www.pedpharma.ru/jour/article/view/127

Internet

https://www.pedpharma.ru/jour/article/view/127

Similar Items